PRIMA Retinal Implant Restored Vision Over 36 Months
The PRIMA device demonstrated sustained central vision improvement in patients with geographic atrophy.
Updated on Oct. 11, 2026 in Biotech
Live Poll
Would you consider a retinal implant to restore vision despite the risk of surgical complications?
The PRIMA retinal implant has shown sustained efficacy in controlling geographic atrophy over a 36-month period, according to data from the PRIMAvera trial. The device, which received European approval in July 2026, restores central vision in patients with retinal degeneration.
Why it matters
This development marks a milestone in using neuro-prosthetics to replace lost photoreceptor function. It offers a potential path for restoring reading ability and advanced task performance in patients suffering from central vision loss.
The PRIMA device achieved an average visual acuity improvement of -0.59 logMAR at 36 months compared to untreated eyes that lost 1.4 lines of vision. Over 80% of patients reported the ability to read letters and numbers at 12 months, with performance gains sustained throughout the study.
The players
Science Corporation
A biotechnology company developing neural interfaces and retinal prosthetics that is now preparing to seek FDA approval.
The details
The PRIMA system uses glasses to capture visual data, which is converted into pulsed near-infrared light. This light is absorbed by a subretinal implant that converts the energy into an electrical current. This current stimulates retinal bipolar and ganglion cells—the nerve cells in the eye that process and transmit signals to the brain—effectively bypassing damaged photoreceptors to restore central vision.
Timeline
July 2026: The PRIMA device received approval for use in Europe.
12 months: Study participants were measured for reading ability and visual acuity.
24 to 36 months: Researchers tracked patient ability to perform advanced tasks.
36 months: The final follow-up period for the PRIMAvera trial was completed.
The Tech Race
The PRIMAvera trial provides a longitudinal performance benchmark for retinal prosthetics, marking a shift from short-term feasibility studies to multi-year efficacy tracking in the field of ophthalmology. By demonstrating sustained results over 36 months, Science Corporation has set a new data standard for competing neural-interface platforms.
The device is currently approved for use in Europe, offering a new treatment pathway for patients with advanced retinal atrophy. Future availability in other regions, including the United States, depends on upcoming regulatory approval processes.
The takeaway
This study confirms that retinal prosthetics can provide durable vision restoration for patients with significant atrophy. Researchers and clinicians should monitor the upcoming FDA application process to determine when this technology may reach markets outside of Europe.
What happens next
Science Corporation plans to initiate the regulatory process to seek FDA approval for the device in the United States.
Further reading
For more developments in neuro-prosthetics and clinical progress, explore our Biotech section.
Live Poll
Would you consider a retinal implant to restore vision despite the risk of surgical complications?
